logo
Plus   Neg
Share
Email

Ford Suspends Production In India, South Africa, Thailand, Vietnam Amid Covid-19

Ford Motor Co (F) announced Monday that it is temporarily suspending vehicle and engine production at its International Markets Group or IMG manufacturing sites due to the growing impact of the coronavirus or Covid-19 pandemic. The decision will affect production in India, South Africa, Thailand and Vietnam.

The company noted that the production suspensions began on March 21 with India. The company stopped operations at Chennai Vehicle Assembly Plant, Sanand Vehicle Assembly Plant, Sanand Engine Plant and Chennai Engine Plant.

The last working day for Vietnam will be March 26, while Thailand and South Africa will stop production after the business on March 27.

The suspensions will continue for several weeks depending on the pandemic situation, national restrictions, supplier constraints and dealer stock requirements.

Ford already suspended vehicle and engine production in North America, Europe and South America. Ford also is requiring employees to work remotely unless they are performing a business-critical job that requires being onsite.

The company's working remotely policy will continue until further notice in a continued effort to help contain the virus.

Ford said it is adjusting its original IMG production schedule and will temporarily suspend production market-by-market.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>